Cargando…
Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects
Extensive damage to nigrostriatal dopaminergic neurons leads to Parkinson’s disease (PD). To date, the most effective treatment has been administration of levodopa (L-DOPA) to increase dopaminergic tone. This treatment leads to responses that vary widely among patients, from predominantly beneficial...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770442/ https://www.ncbi.nlm.nih.gov/pubmed/31480516 http://dx.doi.org/10.3390/biom9090431 |
_version_ | 1783455473850122240 |
---|---|
author | Albarrán-Bravo, Sacnité Ávalos-Fuentes, José Arturo Cortés, Hernán Rodriguez-Sánchez, Marina Leyva-García, Norberto Rangel-Barajas, Claudia Erlij, David Florán, Benjamín |
author_facet | Albarrán-Bravo, Sacnité Ávalos-Fuentes, José Arturo Cortés, Hernán Rodriguez-Sánchez, Marina Leyva-García, Norberto Rangel-Barajas, Claudia Erlij, David Florán, Benjamín |
author_sort | Albarrán-Bravo, Sacnité |
collection | PubMed |
description | Extensive damage to nigrostriatal dopaminergic neurons leads to Parkinson’s disease (PD). To date, the most effective treatment has been administration of levodopa (L-DOPA) to increase dopaminergic tone. This treatment leads to responses that vary widely among patients, from predominantly beneficial effects to the induction of disabling, abnormal movements (L-DOPA induced dyskinesia (LID)). Similarly, experimental studies have shown animals with widely different degrees of LID severity. In this study, unilateral injections of 6-hydroxydopamine (6-OHDA) in the medial forebrain bundle (MFB) produced more than 90% depletion of dopamine in both the striatum and the substantia nigra reticulata (SNr) of rats. Population analysis showed that dopamine depletion levels were clustered in a single population. In contrast, analysis of abnormal involuntary movements (AIMs) induced by L-DOPA treatment of 6-OHDA-lesioned animals yielded two populations: one with mild LID, and the other with severe LID, which are also related to different therapeutic responses. We examined whether the severity of LID correlated with changes in dopamine 3 receptor (D3R) signaling because of the following: (a) D3R expression and the induction of LID are strongly correlated; and (b) dopaminergic denervation induces a qualitative change in D3R signaling in the SNr. We found that the effects of D3R activation on cAMP accumulation and depolarization-induced [(3)H]-gamma-aminobutyric acid ([(3)H]-GABA) release were switched. L-DOPA treatment normalized the denervation-induced changes in animals with mild LID. The D3R activation caused depression of both dopamine 1 receptor (D1R)-induced increases in cAMP production and depolarization-induced [(3)H]-GABA release, which were reversed to their pre-denervation state. In animals with severe LID, none of the denervation-induced changes were reversed. The finding that in the absence of identifiable differences in 6-OHDA and L-DOPA treatment, two populations of animals with different D3R signaling and LIDs severity implies that mechanisms intrinsic to the treated subject determine the segregation. |
format | Online Article Text |
id | pubmed-6770442 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67704422019-10-30 Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects Albarrán-Bravo, Sacnité Ávalos-Fuentes, José Arturo Cortés, Hernán Rodriguez-Sánchez, Marina Leyva-García, Norberto Rangel-Barajas, Claudia Erlij, David Florán, Benjamín Biomolecules Article Extensive damage to nigrostriatal dopaminergic neurons leads to Parkinson’s disease (PD). To date, the most effective treatment has been administration of levodopa (L-DOPA) to increase dopaminergic tone. This treatment leads to responses that vary widely among patients, from predominantly beneficial effects to the induction of disabling, abnormal movements (L-DOPA induced dyskinesia (LID)). Similarly, experimental studies have shown animals with widely different degrees of LID severity. In this study, unilateral injections of 6-hydroxydopamine (6-OHDA) in the medial forebrain bundle (MFB) produced more than 90% depletion of dopamine in both the striatum and the substantia nigra reticulata (SNr) of rats. Population analysis showed that dopamine depletion levels were clustered in a single population. In contrast, analysis of abnormal involuntary movements (AIMs) induced by L-DOPA treatment of 6-OHDA-lesioned animals yielded two populations: one with mild LID, and the other with severe LID, which are also related to different therapeutic responses. We examined whether the severity of LID correlated with changes in dopamine 3 receptor (D3R) signaling because of the following: (a) D3R expression and the induction of LID are strongly correlated; and (b) dopaminergic denervation induces a qualitative change in D3R signaling in the SNr. We found that the effects of D3R activation on cAMP accumulation and depolarization-induced [(3)H]-gamma-aminobutyric acid ([(3)H]-GABA) release were switched. L-DOPA treatment normalized the denervation-induced changes in animals with mild LID. The D3R activation caused depression of both dopamine 1 receptor (D1R)-induced increases in cAMP production and depolarization-induced [(3)H]-GABA release, which were reversed to their pre-denervation state. In animals with severe LID, none of the denervation-induced changes were reversed. The finding that in the absence of identifiable differences in 6-OHDA and L-DOPA treatment, two populations of animals with different D3R signaling and LIDs severity implies that mechanisms intrinsic to the treated subject determine the segregation. MDPI 2019-09-01 /pmc/articles/PMC6770442/ /pubmed/31480516 http://dx.doi.org/10.3390/biom9090431 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Albarrán-Bravo, Sacnité Ávalos-Fuentes, José Arturo Cortés, Hernán Rodriguez-Sánchez, Marina Leyva-García, Norberto Rangel-Barajas, Claudia Erlij, David Florán, Benjamín Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects |
title | Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects |
title_full | Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects |
title_fullStr | Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects |
title_full_unstemmed | Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects |
title_short | Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects |
title_sort | severity of dyskinesia and d3r signaling changes induced by l-dopa treatment of hemiparkinsonian rats are features inherent to the treated subjects |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770442/ https://www.ncbi.nlm.nih.gov/pubmed/31480516 http://dx.doi.org/10.3390/biom9090431 |
work_keys_str_mv | AT albarranbravosacnite severityofdyskinesiaandd3rsignalingchangesinducedbyldopatreatmentofhemiparkinsonianratsarefeaturesinherenttothetreatedsubjects AT avalosfuentesjosearturo severityofdyskinesiaandd3rsignalingchangesinducedbyldopatreatmentofhemiparkinsonianratsarefeaturesinherenttothetreatedsubjects AT corteshernan severityofdyskinesiaandd3rsignalingchangesinducedbyldopatreatmentofhemiparkinsonianratsarefeaturesinherenttothetreatedsubjects AT rodriguezsanchezmarina severityofdyskinesiaandd3rsignalingchangesinducedbyldopatreatmentofhemiparkinsonianratsarefeaturesinherenttothetreatedsubjects AT leyvagarcianorberto severityofdyskinesiaandd3rsignalingchangesinducedbyldopatreatmentofhemiparkinsonianratsarefeaturesinherenttothetreatedsubjects AT rangelbarajasclaudia severityofdyskinesiaandd3rsignalingchangesinducedbyldopatreatmentofhemiparkinsonianratsarefeaturesinherenttothetreatedsubjects AT erlijdavid severityofdyskinesiaandd3rsignalingchangesinducedbyldopatreatmentofhemiparkinsonianratsarefeaturesinherenttothetreatedsubjects AT floranbenjamin severityofdyskinesiaandd3rsignalingchangesinducedbyldopatreatmentofhemiparkinsonianratsarefeaturesinherenttothetreatedsubjects |